Abstract
Purpose
Irinotecan (CPT-11) and 5-fluorouracil (5-FU) are effective cytotoxic agents in the treatment of solid tumours. Continuous i.v. infusion (CI) of 5-FU is significantly more active and better tolerated than bolus i.v. 5-FU. This phase I pharmacokinetic and clinical study evaluated escalating CPT-11 doses administered every 3 weeks combined with a fixed dose of 5-FU CI over 14 days to find the maximum tolerated dose (MTD) of this combined chemotherapy.
Patients and methods
Patients with solid tumours showing failure with previous standard treatment or for whom no established curative therapy existed received CPT-11 i.v. over 90 min (six dose levels were evaluated: 150, 175, 200, 250, 300 and 350 mg/m2) plus a fixed dose of 5-FU CI 250 mg/m2 per day over 14 days. If the MTD was not reached at CPT-11 level 6, then 5-FU was increased to 300 mg/m2. In step 2, 5-FU was administered as a true protracted infusion at the recommended dose found during step 1. In step 3, the recommended dose of CPT-11 was divided and administered in a weekly schedule for 4 weeks combined with a fixed dose of 5-FU CI 250 mg/m2, and then followed by 2–5 weeks rest.
Results
Neutropenia and diarrhoea were the main toxicities, leading to early termination of infusion in three of six patients in level 7. Therefore, CPT-11 350 mg/m2 + 5-FU 250 mg/m2 CI over 14 days was identified as the recommended dose. In step 2, CPT-11 dose had to be reduced to 300 mg/m2 due to toxicity. The weekly schedule of CPT-11 75 mg/m2 + 5-FU 250 mg/m2 CI was feasible with only one patient experiencing severe diarrhoea. No interactions were found in the kinetics parameters of CPT-11 or 5-FU for the different dose levels studied.
Conclusion
CPT-11 300 mg/m2 + 5-FU 250 mg/m2 protracted infusion is the recommended dose for phase II trials, neutropenia and diarrhoea being the dose-limiting toxicities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Conti JA, Kemeny NE, Saltz LB, et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715
Pitot HC, Wender DB, O’Connell MJ, et al (1997) Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910–2919
Rougier P, Bugat R, Douillard JY, et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260
Fukuoka M, Niitani H, Suzuki A, et al (1992) A phase II study of irinotecan, a new derivate of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16–20
Masuda N, Fukuoka M, Kusunoki Y, et al (1992) Irinotecan: a new derivate of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225–1229
Ogawa M (1999) Novel anticancer drug in Japan. J Cancer Res Clin Oncol 125(3–4):134–140
Abigerges D, Chabot GG, Armand JP, et al (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210–221
Rowinsky EK, Grochow LB, Ettinger DS, et al (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427–436
Rothenberg ML, Kuhn JG, Burris HA, et al (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194–2204
De Forni M, Bugat R, Chabot GG, et al (1994) Phase I and pharmacokinetic study of the camptothecin derivate irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347–4354
Takimoto CH, Morrison G, Harold N, et al (2000) Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 18:659–667
Catimel G, Chabot GG, Guastalla JP, et al (1995) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumours. Ann Oncol 6:133–140
Lokich JJ (1987) Colorectal cancer. In: Lokich JJ (ed) Cancer chemotherapy by infusion. Chicago, Precept, pp 291–303
Benedetto P, Borgos M, Morillo G, et al (1986) Chronic continuous infusion of 5-fluorouracil (CCI-FU) in previously untreated patients (pts) with measurable metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 5:92 (abstr)
Kuo S, Finck S, Cho J, et al (1989) Continuous ambulatory infusional 5-fluorouracil (5-FU) chemotherapy in advanced colorectal cancer: a single institutional retrospective study. Proc Am Soc Clin Oncol 8:126 (abstr)
Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308
Investigator’s Brochure—irinotecan, January 1996 (Version 3.0)
Kano Y, Suzuki K, Akutsu M, et al (1992) Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50:604–610
Saltz LB, Kanowitz J, Kemeny NE, et al (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14:2959–2967
Vanhoefer U, Harstrick A, Köhne CH, et al (1999) Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907–913
Aranda E, Carrato A, Cervantes A, et al (2000) Irinotecan (CPT-11) in combination with high-dose infusional 5-FU (TTD schedule) in advanced colorectal cancer (CRC): preliminary results of a phase I/II study. Proc Am Soc Clin Oncol 19:324a
Comella P, Casaretti R, De Vita F, et al (1999) Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. Ann Oncol 10:915–921
Ducreux M, Ychou M, Seitz JF, et al (1999) Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5-FU2 Regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 7:2901–2908
Falcone A, Allegrini G, Masi G, et al (1998) Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion: a phase I study with pharmacokinetic, DNA damage and topoisomerase I/DNA complex evaluation in chemotherapy naïve metastatic colorectal cancer patients. Proc Am Soc Clin Oncol 17:290a
Kakolyris S, Androulakis N, Souglakos J, et al (1998) Phase I study with irinotecan (CPT-11) plus 5-fluorouracil (5-FU 4-DY C.I.) combination in advanced colon cancer. Proc Am Soc Clin Oncol 17:278a
Benhammouda A, Bastian G, Rixe O, et al (1997) A phase I and pharmacokinetic study of CPT-11 and 5-FU in combination. Proc Am Soc Clin Oncol 16:202a
Fonseca R, Goldberg RM, Erlichman C, et al (1998) A phase I study of the combination of CPT-11/5-FU and leucovorin (LV). Proc Am Soc Clin Oncol 17:203a
Saltz LB, Cox JV, Blanke C, et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914
Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky R (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144–146
Rothenberg ML, Eckert JR, Kuhn JG, et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal carcinoma. J Clin Oncol 14:1128–1135
Streit M, Jaehde U, Stremetzne S, et al (1997) Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol 8:1163–1165
Weh HJ, Wilke HJ, Dierlamm J, et al (1994) Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hours infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5:233–237
Douillard JY, Cunningham D, Roth AD, et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047
Robert J, Rivory L (1998) Pharmacology of irinotecan. Drugs Today 34:777–803
Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245–259
Boisdron-Cell M, Craipeau C, Bienza S, et al (2002) Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 49:235–243
Adjei AA, Reid JM, Diasio RB, et al (2002) Comparative pharmacokinetic study of continuous venous infusión fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 20:1683–1691
Acknowledgement
The work described in this paper was supported by a grant from Rhône-Poulenc-Rorer (now Aventis Pharma).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sastre, J., Paz-Ares, L., Carcas, A. et al. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. Cancer Chemother Pharmacol 55, 453–460 (2005). https://doi.org/10.1007/s00280-004-0915-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0915-x